mapping the effectiveness and risks of glp-1 receptor agonists pdf agonism: a transformative approach for managing type-2 diabetes obesity The Role of GLP-1RA Medications

[DOI] [PubMed] [Google Scholar] 58.Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., et al

Nonalcoholic fatty liver disease and type 2 diabetes: Pathophysiological mechanisms shared between the two faces of the same coin

This pattern holds regardless of whether the person exercises or follows a strict diet after stopping the medication, suggesting that these medications alter biological set points rather than simply reducing appetite

1416 Beyond compositional shifts, the functional consequences of dysbiosis are particularly relevant: the microbiota contributes to obesity pathophysiology by driving the production of short-chain fatty acids (SCFAs), modulating bile acid metabolism, and influencing immune and inflammatory pathways